RESI @ TMCx Innovation Challenge Announcement

~ Next Phase Admin ~ Leave a comment

By Natasha Eldridge, Marketing Manager, Life Science Nation

natasha

The RESI Innovation Challenge is taking place in a new home in Houston Texas on June 8th at TMCx and will feature 30 handpicked early stage biotech, medtech, diagnostic and healthcare IT innovators from around the country. These entrepreneurs have been selected by LSN’s scientific validation team to receive a presentation space in the exhibit hall for the full day of the conference to showcase their innovations to investors and fellow entrepreneurs. LSN has found repeatedly that companies presenting in this venue interact with more investors—and with more meaningful dialogues—throughout the course of the day than would be possible in a traditional 15-minute pitch contest.

wp money

To add some friendly competition to the mix, the RESI Innovation Challenge invites all attendees to participate in a virtual investment contest. At the start of the day, each attendee will receive “RESI Cash” to allocate to the entrepreneurs whose technologies they expect will be most influential. The capital that was invested will be tallied up and the top three winners will be featured in our RESI newsletter recap that will go out to LSN’s 20,000 newsletter readership.

  • First prize winner of the RESI Innovation Challenge will receive complimentary subscription to the LSN Investor Platform for a year.
  • Second prize winner will receive two complimentary RESI tickets, to be used within 12 months.
  • Third prize winner will receive one complimentary RESI ticket, to be used within 12 months.

Whether you are an investor, an entrepreneur, or a service provider, make sure you check out the exhibit hall to meet with some of the top innovators in the field and invest your “RESI Cash.” We will see you there!

Hot Life Science Investor Mandate 1: Asian VC Fund Looking Opportunistically In the Life Science Space

~ Next Phase Admin ~ Leave a comment

A venture capital firm that was founded in 2011 and is based in China is managing one fund with committed capital of $140million. The firm typically makes equity investment into life science companies at various stages. The investment size generally ranges from $10 million to $15 million over the life of an investment.  The firm seeks to make 3-5 allocations in the next year. The firm focuses on companies that are based in the China and the US.

The firm is currently looking for new investment opportunities in Biotechnology R&D, Therapeutics & Diagnostics, Pharmaceuticals, Medical Devices and Healthcare IT spaces. The firm is very opportunistic in terms of subsectors and indications. The firm is interested in in-licensing products or technologies for development from companies outside of China, such as US-based companies. The firm also seeks to invest in orphan drugs. Prior investments have included medical device companies, diagnostics companies, CRO and distributors. The firm will consider companies in all stages, depending on the opportunity.

The firm seeks to invest in both private and public companies. The firm has no specific requirements for companies’ management team, revenue or EBITDA.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Corporate Venture Fund of Large Pharma Seeking Early Stage Therapeutics and Devices

~ Next Phase Admin ~ Leave a comment

The corporate venture arm of a large pharmaceutical company is mandated to invest directly in private early-stage life science companies with promising new products that may be future pipeline candidates. The firm seeks to invest across the more expansive business footprint of its parent company. The firm has a global mandate and is currently seeking new equity investment opportunities.

The firm is particularly interested in therapies for rare diseases, oncology, vaccines, and immune mediated diseases. The firm will also invest in breakthrough product candidates in other therapeutic areas such as cardiovascular and diabetes. The firm seeks products that are in preclinical or early clinical development and that have proof-of-concept data. The firm is also willing to consider medical devices targeting these indication

The firm generally co-invests with top tier life science investors and looks to take a minority position (<20%) in each portfolio company. The firm seeks to be a long-term investor with board responsibilities either as a full seat or as an observer.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: Private Equity Firm Seeking Broad Range of Therapeutic Opportunities

~ Next Phase Admin ~ Leave a comment

A private equity fund that was established in 1999 and based in New York, NY, with satellite offices in Princeton, NJ, Cambridge, MA and Brussels, Belgium is currently seeking to make investment in the life science space. The firm controls up to $1.75 billion in assets under management and makes equity investments ranging from $100,000 for academic spin-offs to $150 million in later stage deals. The firm seeks to make investments around the globe with a focus on creating and building companies located within the US and Europe.

The firm is currently looking for companies in the Therapeutics space. For therapeutics the firm is most interested in companies developing novel biologics however companies developing small molecules or biologic substitutes are also considered for investment. The firm is willing to invest in companies with a product anywhere from pre-clinical to phase III of development although they do require a substantial equity position into selected companies. For companies with an asset that is preclinical the firm tends to not get involved if the round is series C or later. The firm is not interested in later stage companies working with primary care technologies.

The firm considers both private and crossover investments and strongly prefers, if not requires to take a board seat into portfolio companies. The firm also prefers to lead or co-lead any investment syndicates and looks to optimize the asset with additional resources beyond the typical venture investment mandate. The firm also requires that the company’s management be able to clearly articulate the mechanisms and functionality of their technology.

The firm is unlike most traditional early stage investors in that they look to act as a partner, taking the company through to commercialization only selling in an M&A transaction if the price is right or access the public markets, but only if it is advantageous to do so.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 4: Corporate VC Arm of Two Healthcare Providers Seeking Healthcare IT and Tech Enabled Devices

~ Next Phase Admin ~ Leave a comment

The corporate venture capital firm that is funded by two substantial healthcare providers makes private equity investments of strategic interest to the systems medical centers and affiliated physicians. The firm makes investment ranging anywhere from $1-$8 million over the life of the investment with the majority of allocations falling in the $5-$7 million range. The firm manages an evergreen structure and is actively looking for new opportunities throughout the United States.

The firm is currently interested in healthcare information technology, tech-enabled medical devices and tech-enabled healthcare services. For medical devices the firm is focused on tech enabled devices and is highly interested in areas of patient monitoring and wearables, among other areas. The firm is also interested in highly innovative hospital hardware and devices that have the potential to significantly lower the cost of the point of care process. The firm generally invests in companies in the series A and B rounds.

The firm is looking for companies with experienced management teams. The firm looks to act as a strategic investor generally taking a board seat. The firm is very open to syndication and general invests along with other institutional investors.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

New Models Emerge to Aid Scientist-Entrepreneurs Journey from Bench to Bedside: Privatized R&D, Studios, Incubators, Accelerators, and New Early Stage VC/PE Funds

~ Next Phase Admin ~ Leave a comment

By Michael Quigley, Director of Research, LSN

mike-2

Developing and commercializing a product in the life science space is notoriously capital intensive and usually involves a high level of risk. To assist with this difficult development process, many organizations have formed that are designing and utilizing new approaches to help move science forward in the early stages of development and clinical research. These include Studios, Incubators, Accelerators, and Funds that aim to create more financially efficient and de-risked models of engagement for companies and investors. The RESI conference will bring together some of the best and brightest of these groups to discuss how they are creating, coaching, and funding life science companies in a more productive manner.

During this panel, moderated by Dennis Ford, CEO & founder of Life Science Nation, the audience will hear from:

Although the forming of virtual companies has shown great promise in reducing costs and keeping companies nimble, along the product development pathway, many inefficiencies remain. This panel will discuss what some of the most cutting-edge groups in the space are doing to tackle these challenges. Conference attendees are sure to gain insight from these individuals who are working to make the life science product development process more streamlined.

resi5-24final-800-300v2

RESI @ TMCx Panel Agenda Finalized: Life Science Luminaries Share Their Expertise Through 16 Panels

~ Next Phase Admin ~ Leave a comment

By Lucy Parkinson, Senior Research Manager, LSN

lucy 10*10

LSN founded the RESI conference with the goal of providing a venue for life science CEOs to build relationships with potential investors and partners. In addition to the opportunity to book up to 16 back-to-back partnering meetings, RESI offers a full day of panel sessions at which CEOs can hear the latest on tactical fundraising straight from leading life science investors. And since each of the 16 sessions is focused on a different life science sector or investor category, RESI’s panelists can speak to a diverse range of companies, offering relevant experience from throughout the biotech, medtech, diagnostic, and healthcare IT fields.

The RESI @ TMCx morning session will offer separate biotech and medtech panels, featuring angels, family offices, and major healthcare corporations that work with startups in these areas. In the afternoon, RESI’s panels will be more topical, with two sessions devoted to new funding alternatives in life science — venture philanthropy and emerging development models — and six sessions focused on fundraising . Finally, in the Tales from the Road session, the audience will hear from start-up CEOs about their recent experiences in raising money to grow their companies.

Throughout these 16 panels, active life science investors will share their insight and provide tactical advice on outreach, positioning, and building the right relationships to move your product forward. Visit the RESI @ TMCx agenda and click on each panel to view the full speaker lineup.

RESI-Agenda